Oskar Ström

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: OSTEOPOROSIS INTERNATIONAL. 2021;32(7):1301-1311

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis

Soreskog E; Borgstrom F; Lindberg I; Strom O; Willems D; Libanati C; Kanis JA; Stollenwerk B; Charokopou M
Article: OSTEOPOROSIS INTERNATIONAL. 2021;32(3):585-594

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

Soreskog E; Lindberg I; Kanis JA; Akesson KE; Willems D; Lorentzon M; Strom O; Berling P; Borgstrom F
Article: OSTEOPOROSIS INTERNATIONAL. 2020;31(8):1525-1533

Real-world effectiveness of osteoporosis treatment in the oldest old

Strom O; Lauppe R; Ljunggren O; Sphangeus A; Ortsater G; O'Kelly J; Akesson K
Article: BONE. 2020;134:115286

Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older

Soreskog E; Strom O; Spangeus A; Akesson KE; Borgstrom F; Banefelt J; Toth E; Libanati C; Charokopou M
Article: ARCHIVES OF OSTEOPOROSIS. 2019;14(1):45

Differing impact of clinical factors on the risk of fracture in younger and older women in the general population and an osteoporosis clinic population

Lauppe R; Akesson KE; Ljunggren O; Spangeus A; Ortsater G; Feudjo-Tepie M; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2019;30(3):601-609

Risk of imminent fracture following a previous fracture in a Swedish database study

Banefelt J; Akesson KE; Spangeus A; Ljunggren O; Karlsson L; Strom O; Ortsater G; Libanati C; Toth E
Article: QUALITY OF LIFE RESEARCH. 2018;27(3):707-716

Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS

Svedbom A; Borgstrom F; Hernlund E; Strom O; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jurisson M; Uuskula A; Lember M; Kallikorm R; Lesnyak O; McCloskey E; Ershova O; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jonsson B; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2018;29(3):557-566

Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS

Svedbom A; Borgstom F; Hernlund E; Strom O; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jurisson M; Kallikorm R; Lember M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Solodovnikov A; Tamulaitiene M; Thomas T; Toroptsova N; Uuskula A; Tosteson ANA; Jonsson B; Kanis JA
Article: ARCHIVES OF OSTEOPOROSIS. 2017;12(1):81

Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.

Karlsson L; Mesterton J; Tepie MF; Intorcia M; Overbeek J; Ström O
Article: OSTEOPOROSIS INTERNATIONAL. 2015;26(10):2401-2411

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2015;26(1):315-325

Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA)

Strom O; Landfeldt E; Garellick G
Article: ARCHIVES OF OSTEOPOROSIS. 2015;10(1):222

Swedish osteoporosis care

Jonsson E; Eriksson D; Akesson K; Ljunggren O; Salomonsson S; Borgstrom F; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(7):1991-1999

The impact of different health dimensions on overall quality of life related to kyphoplasty and non-surgical management

Borgstrom F; Olafsson G; Strom O; Tillman JB; Wardlaw D; Boonen S; Miltenburger C
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(4):1491-1502

Intervention thresholds for denosumab in the UK using a FRAX^A®-based cost-effectiveness analysis

Strom O; Jonsson B; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(3):811-823

The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)-quality of life during the first 4 months after fracture

Borgstrom F; Lekander I; Ivergard M; Strom O; Svedbom A; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jurisson M; Kallikorm R; Lesnyak O; McCloskey E; Nassonov E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jonsson B; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2013;24(1):355-367

Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis

Svedbom A; Alvares L; Cooper C; Marsh D; Strom O
Article: BONE. 2012;51(4):637-642

The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis

Landfeldt E; Strom O
Article: JOURNAL OF ARTHROPLASTY. 2012;27(7):1261-1266

Costs Related to Hip Disease in Patients Eligible for Total Hip Arthroplasty

Rolfson O; Strom O; Karrholm J; Malchau H; Garellick G
Article: OSTEOPOROSIS INTERNATIONAL. 2012;23(8):2201-2209

The association between automatic generic substitution and treatment persistence with oral bisphosphonates

Stroem O; Landfeldt E
Article: HUMAN REPRODUCTION. 2012;27(3):760-769

Patient preferences for characteristics differentiating ovarian stimulation treatments

Landfeldt E; Jablonowska B; Norlander E; Persdotter-Eberg K; Thurin-Kjellberg A; Wramsby M; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2012;23(2):433-443

Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA)

Landfeldt E; Strom O; Robbins S; Borgstrom F
Article: CALCIFIED TISSUE INTERNATIONAL. 2011;89(3):234-245

Gastrointestinal Tolerability and Patterns of Switching in Patients Treated for Primary Osteoporosis: The Swedish Adherence Register Analysis (SARA)

Landfeldt E; Lang A; Robbins S; Strom O
Article: OSTEOPOROSIS INTERNATIONAL. 2011;22(3):967-982

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Jonsson B; Strom O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2011;22(3):955-965

Cost-effectiveness of bazedoxifene incorporating the FRAXA® algorithm in a European perspective

Borgstrom F; Strom O; Kleman M; McCloskey E; Johansson H; Oden A; Kanis JA
Article: BONE. 2011;48(2):380-388

The societal burden of poor persistence to treatment of osteoporosis in Sweden

Landfeldt E; Lundkvist J; Strom O
Article: ARCHIVES OF OSTEOPOROSIS. 2011;6:59-155

Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Ström O; Borgström F; Kanis JA; Compston J; Cooper C; McCloskey EV; Jönsson B
Article: BONE. 2010;47(5):966-974

Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer

Ivergard M; Strom O; Borgstrom F; Burge RT; Tosteson ANA; Kanis J
Article: OSTEOPOROSIS INTERNATIONAL. 2010;21(9):1599-1608

Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting

Strom O; Leonard C; Marsh D; Cooper C
Article: BONE. 2010;47(2):430-437

FRAX® and its applications in health economics-Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

Strom O; Borgstrom F; Kleman M; McCloskey E; Oden A; Johansson H; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2010;21(3):495-505

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXA®

Borgstrom F; Strom O; Coelho J; Johansson H; Oden A; McCloskey EV; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2010;21(2):339-349

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

Borgstrom F; Strom O; Coelho J; Johansson H; Oden A; McCloskey E; Kanis JA
Article: JOURNAL OF MEDICAL ECONOMICS. 2010;13(3):381-392

Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.

Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
Article: JOURNAL OF WOMENS HEALTH. 2009;18(10):1669-1677

Cost-Effectiveness of Hormone Therapy in the United States

Lekander I; Borgstrom F; Strom O; Zethraeus N; Kanis JA
Article: MENOPAUSE INTERNATIONAL. 2009;15(1):19-25

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK.

Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2009;20(1):23-34

Incorporating adherence into health economic modelling of osteoporosis

Strom O; Borgstrom F; Kanis JA; Jonsson B
Article: OSTEOPOROSIS INTERNATIONAL. 2008;19(6):819-827

The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

Zethraeus N; Strom O; Borgstrom F; Kanis JA; Jonsson B
Article: ACTA ORTHOPAEDICA. 2008;79(2):269-280

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

Strom O; Borgstrom F; Zethraeus N; Johnell O; Lidgren L; Ponzer S; Svensson O; Abdon P; Ornstein E; Ceder L; Thorngren KG; Sernbo I; Jonsson B
Article: BONE. 2008;42(2):294-306

Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK -: Results based on the Women's Health Initiative randomised controlled trial

Lekander I; Borgstrom F; Strom O; Zethraeus N; Kanis JA
Article: OSTEOPOROSIS INTERNATIONAL. 2007;18(8):1047-1061

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries -: an economic evaluation based on the fracture intervention trial

Strom O; Borgstrom F; Sen SS; Boonen S; Haentjens P; Johnell O; Kanis JA
Article: BONE. 2007;40(6):1602-1609

The societal burden of osteoporosis in Sweden

Borgstrom F; Sobocki P; Strom O; Jonsson B
Article: EUROPEAN PSYCHIATRY. 2007;22(3):146-152

The economic burden of depression in Sweden from 1997 to 2005

Sobocki P; Lekander I; Borgstrom F; Strom O; Runeson B
Article: OSTEOPOROSIS INTERNATIONAL. 2006;17(12):1781-1793

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting -: Based on the results of the SOTI and TROPOS trials

Borgstrom F; Jonsson B; Strom O; Kanis JA
Visa fler

Alla övriga publikationer

Thesis / dissertation: 2020

Pharmacoepidemiology and health economics of adherence to pharmaceutical fracture prevention

Ström, Oskar
Editorial comment: EUROPEAN RESPIRATORY JOURNAL. 2020;55(4):1902476

NORDSTAR: paving the way for a new era in asthma research

Geale K; Darabi H; Lindh M; Wahl HF; Strom O; Cao H; Alvares L; Dodge R; Loefroth E; Altraja A; Backer V; Backman H; Bjermer L; Bossios A; Aarli BB; Dahlen B; Hilberg O; Janson C; Kankaanranta H; Karjalainen J; Kauppi P; Kilpelainen M; Lehmann S; Lehtimaki L; Lundback B; Sandstrom T; Ulrik CS; Sverrild A; Viinanen A; von Bulow A; Yasinska V; Porsbjerg C
Letter: OSTEOPOROSIS INTERNATIONAL. 2012;23(7):2063-2065

Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.

Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Review: LAKARTIDNINGEN. 2011;108(7):336-339

[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].

Johansson H; Kanis JA; Ljunggren O; Ström O; Svensson O; Mellström D
Review: OSTEOPOROSIS INTERNATIONAL. 2007;18(1):9-23

Cost-effectiveness of the treatment and prevention of osteoporosis -: a review of the literature and a reference model

Zethraeus N; Borgstrom F; Strom O; Kanis JA; Jonsson B

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2024-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för lärande, informatik, management och etik, Karolinska Institutet, 2020

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI